B of A Securities Maintains Buy on ResMed, Raises Price Target to $270
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Lyanne Harrison maintains a Buy rating on ResMed (NYSE:RMD) and raises the price target from $240 to $270.
September 26, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has reaffirmed its Buy rating on ResMed and increased the price target from $240 to $270, indicating a positive outlook on the stock.
The reaffirmation of a Buy rating and an increased price target from a reputable analyst can boost investor confidence and potentially lead to a short-term increase in ResMed's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100